Innate Pharma Reveals Results From TELLOMAK Phase 2 Study With Lacutamab In Mycosis Fungoides
Portfolio Pulse from Benzinga Newsdesk
Innate Pharma announced positive results from its Phase 2 TELLOMAK study, showing that lacutamab is effective in treating mycosis fungoides in heavily pretreated patients. The treatment was well-tolerated, and a virtual KOL event is scheduled for June 11, 2024.
June 04, 2024 | 5:51 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Innate Pharma's Phase 2 TELLOMAK study results indicate that lacutamab is effective in treating mycosis fungoides, with a good safety profile. This positive outcome could boost investor confidence and potentially increase the stock price.
The positive results from the Phase 2 study demonstrate the efficacy and safety of lacutamab, which is likely to enhance investor confidence and drive the stock price up. The upcoming KOL event may further highlight these findings, adding to the positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100